Neos Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsNeos Therapeutics

Neos Therapeutics(NEOS)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Adzenys	Amphetamine	2017-09-15	2024-2038	Narcolepsy , Attention deficit disorder with hyperactivity
Cotempla	Methylphenidate	2017-06-19	2024-2038	Narcolepsy , Attention deficit disorder with hyperactivity , Depressive disorder
Hydrocodone polistirex chlorpheniramne polistirex	Chlorpheniramine polistirex, Hydrocodone polistirex	2012-06-29	2025-2035	Pain , Fever , Postoperative pain , Obstructive lung diseases , Cough , Inflammation , Juvenile arthritis , Menorrhagia , Ankylosing spondylitis , Rheumatoid arthritis , Osteoarthritis , Bursitis , Dysmenorrhea , Gout , Premenstrual syndrome , Sinusitis , Asthma , Common cold , Allergic rhinitis perennial , Urticaria , Obesity , Urinary incontinence , Rhinitis , Whooping cough , Bronchitis , Pharyngitis , Laryngitis , Rheumatic fever

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

Methylphenidate

,

attention deficit disorder with hyperactivity

hyperlipidemias

,

gastrointestinal stromal tumors

,

,

iron-deficiency anemia

,

iron deficiencies

,

,

,

,

small cell lung carcinoma

,

healthy volunteers/patients

,

,

primary myelofibrosis

,

myeloid leukemia acute

,

myeloid leukemia

,

,

hepatocellular carcinoma

,

,

plexiform neurofibroma

,

neurofibromatoses

,

,

,

,

chronic obstructive pulmonary disease

,

,

triple negative breast neoplasms

,

,

,

essential thrombocythemia

,

polycythemia vera

,

,

,

lupus nephritis

,

,

inflammatory breast neoplasms

,

prostatic neoplasms

,

precursor cell lymphoblastic leukemia-lymphoma

,

precursor t-cell lymphoblastic leukemia-lymphoma

,

b-cell chronic lymphocytic leukemia

,

lymphoid leukemia

,

,

wiskott-aldrich syndrome

,

bcr-abl positive chronic myelogenous leukemia

,

,

,

hyperlipoproteinemia type ii

,

organ transplantation

,

homozygous familial hypercholesterolemia

,

cryopyrin-associated periodic syndromes

,

myelodysplastic syndromes

,

,

liver transplantation

,

thrombocytopenic purpura idiopathic

,

thrombocytopenic purpura

,

,

parkinson disease

,

,

,

juvenile arthritis

,

,

,

,

hepatitis b virus

,

,

,

,

vision disorders

,

,

pituitary acth hypersecretion

,

acth-secreting pituitary adenoma

,

,

acute coronary syndrome

,

,

,

pulmonary eosinophilia

,

pancreatic neoplasms

,

,

,

kidney transplantation

,

,

hypercholesterolemia

,

cardiovascular diseases

,

atherosclerosis

,

chronic kidney failure

,

kidney diseases

,

thrombocytopenia

,

,

breast neoplasms

,

,

renal insufficiency

,

,

,

,

chronic renal insufficiency

,

,

renal replacement therapy

,

drug-related side effects and adverse reactions

,

heart transplantation

,

polycystic kidney diseases

,

autosomal dominant polycystic kidney

,

,

,

cystic fibrosis

,

pseudomonas infections

,

type 2 diabetes mellitus

,

diabetes mellitus

,

multiple myeloma

,

plasma cell neoplasms

,

transplantation

,

cytomegalovirus infections

,

communicable diseases

,

,

,

attention deficit disorder with hyperactivity

© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use